Skip to main content
Top
Published in: Diabetologia 10/2005

01-10-2005 | Letter

Reply to comment on: Godsland IF, Jeffs JA, Johnston DG (2004) Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia 47:1157–1166

Authors: I. F. Godsland, D. G. Johnston

Published in: Diabetologia | Issue 10/2005

Login to get access

Excerpt

To the Editor: As we stated in our original paper [1], our intention was to define the level of glycaemia at which pancreatic insulin secretion begins to decline. We were careful throughout to emphasise that we were concerned not with causal relationships but with identifying the principal accompaniments of deteriorating fasting plasma glucose (FPG) levels in the sub-diabetic range. We agree with Abdul-Ghani and DeFronzo that the decline in IVGTT first-phase insulin secretion that accompanies the rise in FPG does not necessarily indicate a causal relationship [2]. Nevertheless, in our study, the decline in first-phase pancreatic insulin secretion was by far the most striking feature that accompanied increasing glucose levels. As Abdul-Ghani and DeFronzo affirm, the important aspect of this decline was that it occurred within ranges of glucose concentrations hitherto considered normal. …
Literature
1.
go back to reference Godsland IF, Jeffs JA, Johnston DG (2004) Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia 47:1157–1166CrossRefPubMed Godsland IF, Jeffs JA, Johnston DG (2004) Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia 47:1157–1166CrossRefPubMed
2.
go back to reference Abdul-Ghani MA, DeFronzo RA (2005) Comment to Godsland IF, Jeffs JA, Johnston DG (2004) Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia DOI 10.1007/s00125-005-1883-3 Abdul-Ghani MA, DeFronzo RA (2005) Comment to Godsland IF, Jeffs JA, Johnston DG (2004) Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia DOI 10.1007/s00125-005-1883-3
3.
go back to reference Godsland IF, Walton C, Felton C, Proudler AJ, Patel A, Wynn V (1992) Insulin resistance, secretion and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 74:64–70CrossRefPubMed Godsland IF, Walton C, Felton C, Proudler AJ, Patel A, Wynn V (1992) Insulin resistance, secretion and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 74:64–70CrossRefPubMed
4.
go back to reference Ley C, Swan J, Godsland I, Walton C, Crook D, Stevenson J (1994) Insulin resistance, lipids, body fat and coagulation factors in males with suspected angina and normal or abnormal coronary angiograms. J Am Coll Cardiol 23:377–383PubMed Ley C, Swan J, Godsland I, Walton C, Crook D, Stevenson J (1994) Insulin resistance, lipids, body fat and coagulation factors in males with suspected angina and normal or abnormal coronary angiograms. J Am Coll Cardiol 23:377–383PubMed
5.
go back to reference Godsland IF, Crook D, Walton C, Wynn V, Oliver MF (1992) Influence of insulin resistance, secretion, and clearance on serum cholesterol, triglycerides, lipoprotein cholesterol, and blood pressure in healthy men. Arterioscler Thromb 12:1030–1035PubMed Godsland IF, Crook D, Walton C, Wynn V, Oliver MF (1992) Influence of insulin resistance, secretion, and clearance on serum cholesterol, triglycerides, lipoprotein cholesterol, and blood pressure in healthy men. Arterioscler Thromb 12:1030–1035PubMed
6.
go back to reference Godsland IF, Crook D, Proudler AJ, Stevenson JC (2005) Hemostatic risk factors and insulin sensitivity, regional body fat distribution and the metabolic syndrome. J Clin Endocrinol Metab 90:190–197CrossRefPubMed Godsland IF, Crook D, Proudler AJ, Stevenson JC (2005) Hemostatic risk factors and insulin sensitivity, regional body fat distribution and the metabolic syndrome. J Clin Endocrinol Metab 90:190–197CrossRefPubMed
7.
go back to reference Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47:31–39CrossRefPubMed Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47:31–39CrossRefPubMed
8.
go back to reference Ozaki K, Okubo M, Mori H, Mito K, Hara H, Kohno N (2002) Decreased insulin secretion and dyslipidemia coexist in subjects with impaired fasting glucose. Diabetes Res Clin Pract 55:159–164CrossRefPubMed Ozaki K, Okubo M, Mori H, Mito K, Hara H, Kohno N (2002) Decreased insulin secretion and dyslipidemia coexist in subjects with impaired fasting glucose. Diabetes Res Clin Pract 55:159–164CrossRefPubMed
9.
go back to reference Stumvoll M, Goldstein BJ, van Haeften TW (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365:1333–1346CrossRefPubMed Stumvoll M, Goldstein BJ, van Haeften TW (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365:1333–1346CrossRefPubMed
Metadata
Title
Reply to comment on: Godsland IF, Jeffs JA, Johnston DG (2004) Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia 47:1157–1166
Authors
I. F. Godsland
D. G. Johnston
Publication date
01-10-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1927-8

Other articles of this Issue 10/2005

Diabetologia 10/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.